Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension (IRE-HT)

9 settembre 2026 aggiornato da: Kam Sang WOO, Chinese University of Hong Kong

The Impact of Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension: A Substudy of Randomized Controlled Trial

Background:

Hypertension (HT) is the most common condition worldwide, predisposing to atherosclerotic disease. However, most HT patients have suboptimal BP control despite anti-HT medications. Isometric resistance exercise (IRE) (e.g. wall squat) may improve BP control, characterized by sustained muscle contraction with minimal change in muscle length and joint angle. Most randomized trials of IRE are short duration and their long-term effects on BP and atherosclerotic complications, particularly in the Chinese, remain unknown.

Study objectives:

(i) To evaluate the impact of IRE on atherogenesis surrogates (brachial flow-mediated dilation, FMD and carotid intima-media thickness IMT).

(ii) To evaluate the impact of IRE on mechanisms of atherogenesis improvement, inflammatory parameters, arterial wall stiffness and biochemical profiles.

Setting:

Randomized samples of 200 HT patients, aged >18years with systolic BP 135-160mHg while on no or stable anti-HT medications.

Design: Randomized controlled IRE trial - stratified randomization with randomization block size of 4.

  1. 100 patients for wall squat exercise of 14 mins each session (2 mins IRE x 4 sets, 2 mins rest in between), 3 sessions per week, for 1 year, plus advice on healthy diet and lifestyle.
  2. 100 control patients (usual care) with advice on diet and healthy lifestyles and simple stretching exercise programme for 1 year.

Main outcome measures:

  1. Brachial FMD and carotid IMT at baseline, 24 weeks and 1 year. (primary outcome)
  2. Carotid-femoral pulse wave velocity (cf-PWV) at baseline and 24 weeks. (secondary outcome)
  3. Important atherosclerosis risk factor parameters at baseline, 24 weeks and 1 year - including fasting serum glucose, lipid profiles, HgbA1-C, creatinine, hs-CRP, CBP, fibrinogen, and interleukin 6 (IL-6). (secondary outcome)
  4. Safety profiles (if any) including CVS event and hospitalization at 1 year.

Expected results:

A group absolute difference in FMD of 1%, and in carotid IMT of 0.06mm between IRE intervention and control groups.

Implications: IRE as suggested will be beneficial to management of HT for atherosclerosis preventions.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

  1. Introduction

    Hypertension (HT) is the most common condition worldwide predisposing to atherosclerotic diseases (stroke, heart attack and peripheral vascular disease), apart from other traditional risk factors [1-3]. However, most HT patients have suboptimal BP control despite anti-HT medications [4]. On this issue, aerobic and dynamic exercise are effective in BP-reduction, but HT-patients often have poor compliance with exercise, mainly because of requirement of additional time, skill training, venue and equipments [5-6]. Isometric resistance exercised (IRE) (e.g. wall squat) may improve BP control, characterized by sustained muscle contractions with minimal change in muscle length and joint angle. However, most randomized trials of IRE have short duration and their long-term effect on BP-reduction, mechanisms and atherosclerosis complications, particularly in the Chinese, remain unknown [7-11].

    Much advance in noninvasive vessel-imaging has been witnessed in past few decades. Brachial flow-mediated dilation (FMD) and carotid intima-media thickness (IMT), have been advocated as surrogate markers for the documentation of early atherosclerosis and evaluation of preventive measures (12-20). Both brachial FMD and carotid IMT can now be measured accurately with high reproducibility, and have been related to cardiovascular outcomes. In clinical context, a 0.1mm increase in carotid IMT has been associated with 41% increase in stroke and 43% increase in acute myocardial infarction over a follow-up period of 2-7 years. [17] An 8% difference in carotid IMT was approximately similar to the kind of difference seen between diabetes and non-diabetes Chinese adults [21).

  2. Aims and Hypotheses to be Tested

    Systemic hypertension has been proven accelerating atherosclerotic process. To further test this initial hypothesis, this interventional substudy aims:

    (i) To evaluate the impact of IRE on atherosclerotic surrogates (brachial FMD and carotid IMT).

    (ii) To evaluate the impact of IRE on mechanisms of BP and atherogenesis reductions, including endothelial function FMD, carotid IMT and arterial wall stiffness (cfPWV), and inflammatory parameters.

  3. Plan of Investigation The brachial FMD and carotid IMT before and after IRE intervention will be compared between the wall-squat and control intervention groups.

3.1 The impact of Isometric resistance exercise (IRE) Intervention on brachial FMD and carotid IMT.

Subjects:

200 HT adults, aged >18 years with SBP 135-160mmHg on AMBP will be recruited. Those with incapacitating osteoarthritis of knee and secondary HT will be excluded.

3.2 Methods: These HT participants will be randomized to practise IRE (100 adults) 14 mins per session, (2 mins IRE x 4sets, 2 mins rest in between), 3 sessions per week, or usual standard care & stretching (yoga) exercise (100 adults).

Week-0 ~ Health Examination, Randomization (IRE vs Yoga), Vascular Study (FMD & IMT), Blood Test, and Arterial wall stiffness (cfPWV)

Week-13 ~ Compliance (adhenence) checking

Week-24 ~ Health Examination, vascular study (FMD & IMT), blood tests, and arterial wall stiffness (cfPWV)

One Year ~ Compliance (adherence) checking, vascular study (FMD & IMT), vessel wall stiffness, and blood Tests

  • Collection of health data:

    1. Questionnaire - All adult subjects will be interviewed and required to complete a detailed questionnaire regarding their individual and family history of cardiovascular diseases, hypertension, diabetes and current use of medications. Information on socio-economic status, tobacco use and lifestyle will be collected.
    2. Health examination - Each participant will receive a health examination and their weight and height, blood pressures, body mass index (BMI) and wait-hip circumference ratio (WHR) will be measured (light clothing and no shoes).
    3. Blood tests: 10ml of fasting blood will be taken for WBC platelet, fasting glucose, HgbA1C, low density lipoprotein cholesterol, hsC-reactive protein, fibrinogen and IL-6.
  • Vascular Studies:

Endothelial function, flow-mediated dilation (FMD) of the brachial artery and carotid IMT will be studied by using high resolution ultrasound.

(i) Endothelial function, (brachial flow-mediated dilation, FMD) will be studied by using high resolution ultrasound, as described previously. [12,22-24] In brief, the diameter of the brachial artery will be measured on B-mode ultrasound images, using a linear array transducer (HF L38) with a median frequency of 13-6MHz and a standard Sonosite (MicroMaxx) system. Forearm tourniquet cuff placement will be applied to induce reactive hyperemia on deflation. Scans of brachial artery 10cm proximal to elbow will be acquired at rest, during reactive hyperemia (to induce flow-mediated endothelium-dependent dilation, FMD). FMD will be expressed as % of dilation from baseline vessel diameter normalized with vessel strain. Hyperemia is calculated as the % increase in blood flow after cuff deflation compared with baseline.

(ii) Carotid intima-media thickness (CIMT) measurement - B-mode ultrasound examinations will be performed using a 10-5 probe, with a 7.5 MHz scanning frequency linear array transducer. All carotid scans will be performed by a single operator after a predetermined, standardized scanning protocol for the right and left carotid arteries as described by Salonen and Salonen [16] and Touboul et al [19], using images of the far wall of the distal 10 mm of the common carotid arteries. All scans will be recorded on super-VHS videotape for subsequent off-line analysis for intima-media thickness (IMT), using a verified automatic edge-detecting and measurement software package as described previously. [19-24] The intra-observer variability of mean IMT is 0.003 to 0.011mm (CV 0.998%).

3.3 Outcomes

3.3.1 Primary outcomes: Vascular Parameters: Brachial FMD (%) and Carotid IMT (mm) at baseline, 24 weeks and 1 year.

3.3.2 Secondary outcomes: (i) Carotid femoral pulse wave velocity, cfPWV (mm/sec) at baseline and 24 weeks.

(ii) Other important traditional atherosclerosis risk factors: BMI (weight kg/ height m^2), glucose (mmol/l), lipid profiles (mmol/l), HgbA1-C (%), creatinine (umol/L), haemoglobin (g/dl), hsCRP (mg/l), Fibrinogen (mg/dl) and IL-6 (pg/ml) at baseline, 24 weeks and 1 year.

3.3.3 Safety profiles (if any) including CVS event and hospitalization at 1 year,

4. Compliance with Declaration of Helsinki. The design, methodology and conduction of project are in compliance with Declaration of Helsinki.

5. Data processing and analysis:

(5.1) Power Calculation: The Proc Power in the STS 9.2 statistical packages (SAS Institute Inc. Cary. NC, US) was used to calculate the sample size for FMD and carotid IMT. Data from our previous studies on Chinese adults in Hong Kong reported FMD was in 6-8% +/- 1.3%, and carotid IMT was 0.55-0.68mm +/- 0.1mm. On the assumption of post IRE brachial FMD will improve to 6.7-8.7 +/- 1.4%, and carotid IMT will reduce to 0.51-0.61mm +/- 0.11mm, recruitment of 200 Chinese adults (100 in each group) will be adequately powered (85%) to detect a group difference in brachial FMD of 1.2% and in carotid IMT of 0.06mm (12%), at 1 year between the two treatment groups.

(5.2). Data Analysis: Statistical Analysis System SPSS version 28 (SAS Institute Inc., Cary, NC, US) will be used for all statistical analyses. Descriptive methods will be used to describe characteristics of cardiovascular risks. The primary endpoints are AMBP, brachial FMD and carotid IMT; serological inflammatory biomarkers (Neutrophil/ monocyte ratio and Platelet), hsCRP, fibrinogen and IL-6 are secondary endpoints. Students' T-tests will be used to detect the group differences in brachial FMD and carotid IMT. Multivariable linear and logistic regressions will be used to calculate the risk magnitude by IRE vs usual care and stretching exercise interventions, and to control potential confounders such as traditional cardiovascular risk factors.

Tipo di studio

Interventistico

Iscrizione (Stimato)

200

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Shatin, Hong Kong
        • Reclutamento
        • The Chinese University of Hong Kong, Department of Medicine & Therapeutics
        • Contatto:
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

Sì

Descrizione

Inclusion Criteria:

  1. asymptomatic clinically stable adults
  2. aged >18 years
  3. Both genders
  4. Suboptimal BP (on stable medication) with SBP 135-160mmHG on ambulatory BP monitoring (AMBP)
  5. Agreeable to no drug changes in coming 1 year 24 weeks
  6. Agreeable to provide informed written consent form
  7. Agreeable to have AMBP and ultrasonic (FMD & IMT) scan third (baseline, 24 weeks and preferably 1 year)

Exclusion Criteria:

  1. relative contraindications to AMBP (e.g. atrial fibrillation)
  2. severe osteoarthritis of knee
  3. known secondary HT
  4. pregnancy/breastfeeding
  5. active malignancy
  6. Serious coronary profiles, (unstable angina), renal or hepatic derangement
  7. Need to change medications for control BP at 24 weeks ( SBP>160 mmHg)

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Anti HT + Isometric Resistance Squatting Exercise (100 Adults)
A more linear thigh-leg squatting angle is allowed in initial 2 weeks, but aiming at 90 degree thigh-leg angle after 4 weeks.
14 minutes per session (2 mins x 4 sets, 2 mins rest in between, 3 session per week)
Comparatore attivo: Anti HT + Stretching Exercise (100 Adults)
A liberal leg stretching excerise will be practised
2 mins x 4 sets, 2 mins rest in between, 3 sessions per week

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
The Impact of Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension
Lasso di tempo: Baseline, 24 weeks and 1 year
Changes in Brachial FMD (%)
Baseline, 24 weeks and 1 year
The Impact of Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension
Lasso di tempo: Baseline, 24 weeks and 1 year
Changes in Carotid IMT (mm)
Baseline, 24 weeks and 1 year

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
The Impact of Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension
Lasso di tempo: Baseline and 24 weeks
Changes in Carotid femoral pulse wave velocity, cfPWV (mm/sec)
Baseline and 24 weeks
The Impact of Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension
Lasso di tempo: Baseline, 24 weeks and 1 year

Other important traditional atherosclerosis risk factors:

Changes in BMI (weight kg/ height m^2)

Baseline, 24 weeks and 1 year
The Impact of Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension
Lasso di tempo: Baseline, 24 weeks and 1 year
Changes in Fasting Glucose (mmol/l)
Baseline, 24 weeks and 1 year
The Impact of Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension
Lasso di tempo: Baseline, 24 weeks and 1 year

Changes in Fasting Lipid profiles (mmol/l)

  1. Changes in high density lipoprotein cholesterol (HDL-C) (mmol/l)
  2. Changes in low density lipoprotein cholesterol (LDL-C) (mmol/l)
  3. Changes in Triglyceride (TG) (mmol/l)
Baseline, 24 weeks and 1 year
The Impact of Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension
Lasso di tempo: Baseline, 24 weeks and 1 year
HgbA1-C (%)
Baseline, 24 weeks and 1 year
The Impact of Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension
Lasso di tempo: Baseline, 24 weeks and 1 year
Creatinine (umol/L)
Baseline, 24 weeks and 1 year
The Impact of Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension
Lasso di tempo: Baseline, 24 weeks and 1 year
Haemoglobin (g/dl)
Baseline, 24 weeks and 1 year
The Impact of Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension
Lasso di tempo: Baseline, 24 weeks and 1 year
hsCRP (mg/l)
Baseline, 24 weeks and 1 year
The Impact of Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension
Lasso di tempo: Baseline, 24 weeks and 1 year
Fibrinogen (mg/dl)
Baseline, 24 weeks and 1 year
The Impact of Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension
Lasso di tempo: Baseline, 24 weeks and 1 year
IL-6 (pg/ml)
Baseline, 24 weeks and 1 year

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Kam Sang Woo, Chinese University of Hong Kong

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

16 aprile 2025

Completamento primario (Stimato)

30 luglio 2027

Completamento dello studio (Stimato)

30 dicembre 2027

Date di iscrizione allo studio

Primo inviato

17 settembre 2025

Primo inviato che soddisfa i criteri di controllo qualità

23 giugno 2026

Primo Inserito (Effettivo)

24 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

11 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 settembre 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 2022-618-T

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

There is a plan to make IPD and related data dictionaries available. All IPD that underline results in a publication.

Periodo di condivisione IPD

These materials will be available and shared on reasonable requests to Prof KS Woo from January 2025 till 30 December 2027

Criteri di accesso alla condivisione IPD

These materials will be available and shared on reasonable requests to Prof KS Woo from January 2025 till 30 December 2027 (kamsangwoo@cuhk.edu.hk/ crec@cuhk.edu.hk)

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .